Skip to main content
. 2019 Mar 30;9(2):281–297. doi: 10.1007/s13555-019-0291-4

Fig. 1.

Fig. 1

Deterministic sensitivity analysis results of ICER for Japanese adults aged ≥ 65 years by analytical perspective (top 10). a Payer’s perspective; b societal perspective. HZ herpes zoster, ICER incremental cost-effectiveness ratio, PHN postherpetic neuralgia, QALY quality-adjusted life year, RZV recombinant zoster vaccine, YOA years of age